PMID: 25743817Mar 7, 2015Paper

Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer

Asian Pacific Journal of Cancer Prevention : APJCP
Dogan YazilitasKadri Altundag

Abstract

Adding taxanes to adjuvant antracycline and cyclophosphamide (AC) in combination may provide significant improvement in node-positive and high risk node-negative breast cancer (BC) patients. However, the optimal dose and the role of dose-dense (DD) chemotherapy have yet to be determined. The aim of this study was to compare the efficacy of a DD paclitaxel (P)-AC combination with conventional weekly P-AC or docetaxel D-AC combinations in patients with node-positive breast cancer. Newly diagnosed 280 node-positive BC patients diagnosed from 1998 to 2013 in three clinics were retrospectively analyzed. Demographic and medical data were collected from the medical charts. Patients were categorized to 3 groups according to treatment arms: arm A, ddAC-P; arm B, weekly P and AC combination; and arm C; T and AC combination. Adjuvant trastuzumab was added for HER2-positive patients. Kaplan-Meier survival analysis was carried out for disease free survival (DFS) and overall survival (OS). The log-rank test was used to examine the statistical significance of the differences observed between the groups. Two-sided P values <0.05 were considered statistically significant. Of the total of 280 patients, 101 were in arm A, 114 in arm B and 65 in a...Continue Reading

References

Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Georgiana K EllisTove Thompson
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Marc NabholtzUNKNOWN TAX 306 Study Group
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I Craig HendersonLarry Norton
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gianni BonadonnaPinuccia Valagussa
Dec 8, 2005·Journal of the National Cancer Institute·Marco VenturiniPaolo Bruzzi
Apr 19, 2008·The New England Journal of Medicine·Joseph A SparanoNancy E Davidson
Jul 4, 2009·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Morihiko KimuraUNKNOWN Adjuvant CEF Research Group for Breast Cancer
Nov 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick G MorrisChau T Dang
Dec 3, 2010·The New England Journal of Medicine·Miguel MartínUNKNOWN GEICAM 9805 Investigators
Jul 13, 2013·Journal of the National Comprehensive Cancer Network : JNCCN·Richard L TheriaultUNKNOWN National Comprehensive Cancer Network
Aug 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandra M SwainNorman Wolmark
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Apr 11, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Ajay GogiaDaya Nand Sharma

❮ Previous
Next ❯

Citations

Mar 4, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Diriba Alemayehu GadisaGetnet Yimer
Sep 1, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Quan-Bin ZhaXin-Yu Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Carcinoma, Lobular

Lobular carcinoma is an invasive type of breast cancer in which lobules, areas of the breast that produce milk, undergo malignant transformation. Here is the latest research.